We present a critical review of the recent literature and discuss the development and prospective view of the evaluations of transrectal ultrasound with regard to prostate malignancy. We illustrate this with personal experiences. Material and Methods: Based on a critical evaluation of clinical data we address the apparent shortcoming of greyscale transrectal ultrasonography in the assessment of prostate cancer. New developments and future possibilities are also discussed.
Introduction
During the past years the reported increase of prostate carcinoma prevalence and incidence 1 has led to growing concern because of the medical and economical consequences. The need for the most effective health care at the most reasonable cost, even in the richest countries is evident. Prostate cancer remains the most frequently diagnosed malignancy in men in the US and the second leading cancer-related cause of death in elderly males. 2 The incidence in the US increased from 165000 cases in 1993 to an estimate of 318000 in 1996. 3 This phenomenon is believed to be due to longer life expectancy, growing prostate awareness and new developments in prostate cancer detection. 4 New data of the American Cancer Society show a slight decrease in the number of patients estimated to be diagnosed with prostate cancer in 1998. The disease is diagnosed at a younger age and at an earlier stage. 5 The detection of prostate carcinoma is currently based on three clinical parameters: digital rectal examination (DRE), serum prostate speci®c antigen (PSA) and transrectal ultrasound of the prostate (TRUS).
Since the introduction of TRUS by Watanabe et al in 1968 6, 7 TRUS has evolved signi®cantly and the application of TRUS to evaluate the condition of the prostate has been well established. Some of the possibilities are undisputed, such as volume measurement of the prostate and guidance of prostate biopsies to areas of interest. TRUS as a means for early detection of prostate carcinoma is still a point of discussion due to the non-uniform appearance of malignancy at ultrasound. This non-uniform appearance of malignancy has resulted in the introduction of random sextant biopsies in case no suspicious lesion is visible and sextant biopsies are routinely added to lesion-directed biopsies in case of suspicious ultrasound appearances. 6 Although the sextant biopsy approach has improved the detection of prostate cancer, the sensitivity and speci®city to diagnose cancer are disappointingly low, with the number of false negatives in a single biopsy session reported as 30 ± 45%. 9, 10 On the other hand, the current indications for biopsies result in a high false positive rate, as high as 68% in a group of 232 patients with one or more positive test. 11 Research in recent years has focused on identifying new methods for prostate carcinoma detection as well as improving the existing ultrasound technology.
Recent developments in computer technology have resulted in more powerful ultrasound machines with new technological modalities such as 3D imaging and harmonic imaging. The promising improvements of Doppler ultrasound imaging when adding ultrasound contrast agents are being investigated too. While the clinical implications of these new developments are currently unclear, some of the results are encouraging.
In this paper we present a critical review of the recent literature and discuss the developments and prospective view of the evolution of ultrasound techniques, illustrated by personal experiences.
Grey scale imaging
The dilemma, the limitations
The detection of prostate cancer is currently based on three clinical parameters: digital rectal examination (DRE), serum prostate speci®c antigen (PSA) and transrectal ultrasound (TRUS). Most carcinomas are localised in the peripheral zone; 12 some of these tumours are palpable on DRE and digital guided biopsies can be performed to con®rm or exclude the presence of malignancy. However, approximately one third of the carcinomas are non-palpable. 13 In case of non-suspicious palpation but elevated PSA level ( b 4.0ng/ml) TRUS and ultrasound guided biopsies arc necessary in order to evaluate possible prostate pathology.
Asymmetric enlargement of the prostate suggests possible malignancy. Also the texture of the prostate tissue on TRUS may indicate a malignant lesion. For instance, hypoechoic lesions have a 17 to 57% chance of being malignant. 14 ± 21 Biopsies of these lesions can be guided by TRUS. Yet, a signi®cant part (at least 27%) of the carcinomas of the prostate is isoechoic. 22 This means that not all tumours are visible on TRUS. Some authors describe up to 56% of carcinoma found in areas that appeared normal on TRUS. 23 To illustrate this we have two examples. Figure la shows a TRUS image of a prostate with a clear hypoechoic lesion on the right side of the prostate.
After biopsies this lesion proved to be malignant, and a radical prostatectomy was performed. Figure lb shows the histology specimen. Figure 2a shows a TRUS image of a prostate, without a visible hypoechoic lesion. The general appearance is isoechoic. This patient had positive prostate biopsies and a radical prostatectomy was performed. Figure 2b shows the histology specimen of the prostate. The malignancy proved to be mainly on the ventral side of the prostate.
It is therefore concluded that not all malignant tumours are seen as lesions in ultrasound, and that not all lesions seen in ultrasound are malignant tumours.
In case of an elevated PSA and no suspicious lesion on DRE and TRUS, no information on the best location for biopsy is available. Sextant peripheral zone biopsies have been introduced for random systemic sampling of the prostate, as was ®rst described by Hodge et al. 24 Sextant biopsies resulted in better detection of prostate carcinoma in prostates with normal appearance on TRUS. 25 The value of systemic biopsies has been the subject of a number of recently published papers. Hamerer et al 25 
Figure 1a
With conventional grey scale ultrasonography a clear hypoechoic lesion is seen on the right dorsal side of the prostate.
Figure 1b
The matching pathology specimen, which shows prostate carcinoma (Gleason-score 6) where the hypoechoic lesion was seen.
performed systemic sextant peripheral zone biopsies in men with elevated PSA and/or abnormal DRE and found prostate carcinoma in 20% with prostates that appeared normal on ultrasound, and would not have been detected by ultrasound lesion guided biopsies.
On the other hand, Norberg et al 26 developed a biopsy model in which 8 ± 10 biopsies were taken. When comparing the results, systemic sextant peripheral zone biopsies would have missed 15% of the carcinomas they found. Eskew et al 27 also reported on the value of additional biopsies to the systemic sextant peripheral zone biopsies in a model which they called the ®ve-region biopsy model. Of the carcinomas 35% were found in the regions added to the standard sextant biopsies.
Regarding men with a strong suspicion for prostate cancer because of an abnormal DRE and/or elevated PSA, it is recommended to repeat the biopsy series if the ®rst series is negative. Keetch et al 28 reported a 96% prostate carcinoma detection with the ®rst two series of systemic sextant peripheral zone biopsies. All these investigations underline the importance for systemic peripheral zone biopsies in case of abnormal DRE and/or elevated PSA with no abnormality on TRUS, if the outcome of the biopsies have clinical implications regarding therapeutic consequences. We reviewed the value of random biopsies in the diagnosis of prostate carcinoma, and all studies indicate that repeat biopsies will improve the cancer detection rate and that a signi®cant number of patients will be incorrectly diagnosed with clinically benign disease when using the outcome of a single biopsy session. 29 We investigated the predictive values of DRE, PSA and TRUS and the combination of these diagnostic tests in the diagnosis of prostate cancer in a selected group of 232 patients suspected of having prostate cancer. 30 By combining the tests we found a sensitivity of 75%, a speci®city of 85% and a diagnostic accuracy of 80%.
TRUS is an easy to use diagnostic tool in the hands of an experienced observer. The application of TRUS for prostate volume measurements and biopsy guidance is used broadly in the urologic practice. The low sensitivity and speci®city for prostate cancer detection limits the role of conventional grey scale TRUS as a tumour diagnostic.
Improved ultrasound imaging
Despite the improved detection of prostate cancer using systemic peripheral zone biopsies, the reported sensitivity and speci®city of TRUS in detecting prostate carcinoma is disappointingly low, with the number of false negatives in a single biopsy session reported at 30 ± 45.6%. 9, 10 The ultimate goal in the evaluation of prostatic diseases is to improve the early detection of prostate cancer and avoid unnecessary biopsies and to increase diagnostic information obtained from the removed tissue core. One way of improving the indications for biopsies in ease of suspected prostate cancer is to improve imaging of the prostate gland. Grey scale TRUS is recognised as a possible method for detecting impalpable tumours. Despite its relatively high sensitivity, its speci®city has been consistently low (20 ± 60%). 31 We found a sensitivity of 84% and a speci®city of 67% using TRUS in the detection of prostate cancer. 30 This is the main reason that grey scale TRUS has limited applicability in screening for prostate cancer. To illustrate this, Bangma et al 32 described the value of screening in the detection of prostate cancer in a group of 1726 men. After initial analysis of the DRE, PSA and TRUS a total of 308 biopsies were performed, and 67 prostate carcinomas were detected. In this group, the sensitivity was 54%, the speci®city 56% and the diagnostic accuracy 56%. Ameliorating the predictive value of TRUS has important implications. It might enable a more selective biopsy policy or obviate the necessity for biopsy altogether.
Computer assisted analysis of ultrasound images
At our department, computer assisted TRUS of the prostate has been investigated to overcome the inter-observer Figure 2a With conventional grey scale ultrasonography of the prostate no lesion is seen. Because biopsy showed a prostate cancer on the right side, the patient was scheduled to undergo radical retropubic prostatectomy.
Figure 2b
The matching pathology specimen, which shows evident prostate carcinoma (Gleason-score 7) on the right ventral side of the prostate. In retrospect this malignant area is slightly hypo-echoic in the grey-scale images.
variability and improve the low predictive value of TRUS. 33 Computer interpretation can improve the reproducibility of grey scale interpretation and may reveal information not perceptible by the human eye. The computer interpretation of TRUS images was based on a statistical method. The system uses image-processing algorithms to analyse grey scale transrectal images and colour code these images according to the probability of malignancy. In the learning phase of the project texture grey scale parameters of biopsy images were correlated with histological ®ndings of the biopsies re¯ected in a binary decision tree. 33, 34 Such a tree describes hierarchical decisions made to partition the parameter space into hypercubes corresponding to speci®c disease. In the patients analysed a sensitivity of 75% and a speci®city of 78% was obtained with the use of the automated cancer detection. The diagnostic accuracy achieved was 75%. 14 Although these results suggest an increase in the diagnostic value of transrectal ultrasound of the prostate, the diagnostic accuracy should increase further before the system can be used on a routine basis.
Doppler imaging
The use of Doppler technique in combination with grey scale TRUS has the potential to provide a useful addition for tumour detection. It is well recognised that vascularisation in prostate cancer alters during the development of the tumour. 35 Tumour models demonstrate a relationship between vascularity and tumour size, being avascular at less than 2mm in diameter, being uniformly vascular at up to 1cm 3 , and developing central necrosis beyond this size with resultant loss of vascularity. 36 Investigators have studied the microvessel density in prostate carcinoma as a prognostic and therapeutic aid. 37, 38 Because tumour growth is associated with neovascularisation, it is assumed that malignant tissue of the prostate has altered, possibly resulting in changes in blood¯ow, which could be visualised with the use of Doppler ultrasonography. If one could visualise this aspect accurately, one might well be able to improve the diagnosis of prostate cancer by ultrasound imaging. One of these possibilities is the use of frequency Doppler ultrasonography (FDU). FDU imaging provides realtime visualisation of blood¯ow additional to grey scale imaging. During FDU examination, shifts in frequency of the transmitted ultrasound signal re¯ected by targets moving with respect to the transducer are recorded. The resulting frequency shift is proportional to the speed of the moving target, and velocity can be calculated if the angle between the ultrasound beam and the movement direction is known. FDU displays a coloured overlay over the grey scale information by encoding the frequency shift of pulsed Doppler signals. The FDU technique enables the user to evaluate the local vascularity status and identify possible vascularity disorders. Figure 3 shows an example of a FDU investigation of a prostate. The Doppler signals represent the frequency shift of the detected Doppler signal. Some large vessels are seen on the left side of the prostate, and some smaller vessels in the peripheral zone.
Preliminary overall results with FDU scanning of the prostate suggested limited improvement over grey scale ultrasonography in the differentiation of cancer from other processes affecting the prostate. 39, 40 Also, Kelley et al 41 compared grey scale TRUS with FDU TRUS in patients undergoing prostate biopsies. Biopsies were either targeted to grey scale or FDU abnormalities with a variable number of random or systemic biopsies performed. With this method a sensitivity of 96% for grey scale TRUS was found in identifying malignancy and a positive predictive value of 53%. By adding FDU to TRUS the positive predictive value would increase to 77% but sensitivity would be reduced to 87%. Newman et al 42 correlated the ®ndings at prostate FDU with those of sitespeci®c transrectal core biopsy. They concluded that focal increased peripheral zone¯ow at FDU is associated with a high likelihood of focal carcinoma of the prostate at histological examination. Therefore FDU may improve biopsy yield by enabling determination of the appropriate site for systemic biopsies in patients with elevated PSA and no focal grey scale abnormalities. Cho et al 43 also found that FDU could be of value for the identi®cation of diffuse prostate lesions. Rifkin et al 44 concluded that FDU is important in the detection of suspicious lesions of the prostate. Less experienced and more experienced investigators will develop greater con®dence with FDU. Cornud et al 45 compared TRUS and FDU in the detection of prostate cancer and found a sensitivity of 90% and 78% respectively and a speci®city of 46% and 80% respectively. Non palpable cancers with hypervascularized lesions showed a signi®cant (P`0.001) higher Gleason score (6.5 AE 1.1) than non-hypervascularized lesions (Gleason 5.5 AE 0.9). Lavoipierre et al 46 indicated that FDU complements grey scale imaging and should become a routine part of TRUS imaging of the prostate to improve detection and targeting of lesions. However, negative ®ndings at both FDU and grey scale TRUS should not preclude the performance of random or systemic prostate biopsies. Ismail et al 47 investigated the value of FDU of the prostate in predicting the biological behaviour of prostate cancer. They found a correlation between colour Doppler¯ow within the tumor and the overlying capsule appears with both tumor grade and stage, respectively. Detection and grading of color-coded¯ow within biopsy-proven cancers may identify patients with a high likelihood of biochemical relapse.
A more recent development of Doppler ultrasonography has resulted in a method which is called Power Doppler ultrasonography (PDU). PDU is based on estimating the integrated Doppler power spectrum. In PDU the hue and brightness of the colour signal represent the total energy of the Doppler signal, which is related to the number of red blood cells producing the Doppler shift. 48 Figure 4 shows the same prostate as shown in Figure 3 . Using PDU an increased number of coloured signals is seen. Periurethral and capsular vessels are better identi®ed.
It is reported that PDU has several advantages over FDU. PDU is essentially angle independent, does not show aliasing and, in contrast to FDU, it does not give information on direction or velocity, and should increase the usable dynamic range of the Doppler imager. With all these advantages PDU is believed to be more sensitive to low¯ow than FDU. 49 Recent studies have investigated the possible use of PDU in regard to FDU. Because of the relation between the number of moving parts in the PDU signal and the amplitude, the signal can be quanti®ed. Therefore, PDU seems to be promising in determining fractional moving blood volume 50 and in estimating tissue perfusion. 51 Sakarya et al 52 presented a study to determine the value of PDU in the diagnosis of prostate cancer in a small group of patients with a suspicion of prostate cancer. They concluded that PDU seemed to increase the predictive value of TRUS, and could help improve the biopsy yield by determining a more appropriate site for biopsy.
Because of increased computer power the role of FDU and PDU images receives increased interest. A greater spatial and temporal resolution can be obtained, and better image processing and more sensitive colour image will result.
Contrast agent imaging
As stated before, restrictions can be found in Colour Doppler ultrasound imaging. In particular, detection of low¯ow in small vessels is dif®cult because of limited spatial resolution. Also, detection of low volume¯ow is problematic because slow movement results in frequency shifts below the noise level and are therefore not detected. However, the intensity of the detected Doppler signal is directly related to the number of moving particles. It is technically possible to increase the number of moving particles by adding ultrasound contrast to the blood pool. The coincidentally detected effect of microbubble ultrasound contrast in 1968 53 provides a method to detect and measure organ and tissue perfusion.
Contrast agents fall into two main categories. The ®rst are¯uids, like per¯uoro chemicals (PFCs) through which ultrasound moves relatively slowly, which are taken up by the reticuloendothelial system or diffuse preferentially into tumours via their more permeable vascular system. The PFCs are organic compounds in which all of the hydrogen atoms are replaced by¯uorine. They are strongly echogenic. Metastases in the liver are seen more clearly, either as relatively echo-poor regions or as positive contrast with diffuse or ring-like enhancement. A disadvantage of PFCs is the 24 ± 48 hour delay before the enhancement appears. 54, 55 The second category of contrast agent are microbubblē uids, containing captured air or gas bubbles that act as re¯ectors. Unlike the diffusible agents, the bubbles remain within the circulation. As the bubbles move corresponding to the hemodynamic behaviour, they can be detected by Doppler ultrasonography until they dissolve. To produce contrast enhancement in the peripheral organs the microbubbles must be small enough to pass the lung capillaries (`10 mm). The fact that the surface tension of a bubble increases exponentially with reducing diameter determines that such small microbubbles dissolve very rapidly and do not survive long enough after intravenous injection to provide clinically useful systemic enhancement unless protected by coating. If the microbubbles are coated with a semirigid membrane (such as lipids, albumen or biodegradable plastic), their dissolution can be delayed. The alternative is to lower the surface tension by creating a protective molecular ®lm around each microbubble by adding a trace amount of palmatic acid. Only recently, contrast agents have been developed that can survive the pulmonary vascular system to reach peripheral organs including the prostate.
The use of ultrasound contrast in combination with FDU or PDU can provide important additional information to visualise changes in blood¯ow. The spatial information of the contrast-enhanced ultrasonography may be used to create 3D reconstruction of the vascular anatomic tree, whereas the temporal information can be used to study local dynamic behaviour of tissue blood supply by analysing the time ± intensity curves of the signal. By analysing the blood¯ow patterns in areas of interest, information may be gained to discriminate malignant from normal tissue. Ragde et al 56 reported on a small group of patients in which they used contrast enhanced ultrasonography to image the prostate. The authors conclude that contrast enhanced ultrasonography promises to be a useful technique for better imaging of prostatic blood¯ow and might allow for a more accurate identi®cation of malignant lesions. They also expect sensitivity to increase with accumulating examiner experience. Additional to the diagnostic applications, contrast ultrasonography can also provide a method for follow up of therapy and treatment, as indicated by Cosgrove. 57 With increasing computer power, modalities such as the 3D reconstruction of ultrasound images become clinically available. This technique could improve imaging in foetal malformation, volume measurements, follow up of treatment, and detection of small lesions. 58 Several clinical applications are feasible in parenchymatous organs (mainly liver and prostate), hollow viscera (bladder, gallbladder), and peripheral and central vessels. Campani et al conclude that 3D volume reconstruction of B-mode, FDU and PDU could well compete with computed tomography and magnetic resonance 3D reconstruction. 59 Our initial experiences of 3D reconstruction of contrast enhanced ultrasound images have been described by Bogers et al. 60 In a small group of patients with a suspicion of having prostate cancer we correlated the outcome of 3D contrast enhanced PDU with the histology of the standard biopsies. An increase in sensitivity for tumour detection was found from 38% to 85% when using contrast enhancement in combination with 3D PDU, while speci®city was found to be 80% for both modalities. We conclude that 3D contrast-enhanced PDU offers promising new research, which might prove to be of use in prostate cancer detection in the future. Figure 5 shows the 3D contrast enhanced PDU of the same prostate as in Figure 2 . No lesion was seen using conventional grey scale imaging. With unenhanced PDU we saw some coloured signal in the ventral side of the prostate. Using 3D contrast enhanced PDU the abnormal blood¯ow signal on the ventral side is more outspoken. This lesion correlated with the pathology of the radical prostatectomy specimen.
The investigations described above are spatial investigations allowing the display of anatomical structures of the vascular tree. 3D information was used for tumour localisation and therapeutic follow up. We described the use of temporal information for tumour localisation. 61 Assuming tumour growth disturbs the normal vascularity of the prostate, creating multiple small vessels and arterial ± venous shunts causing reduction of blood¯ow resistance, a method is described to identify the tumouraffected side of the prostate using time ± intensity curve analysis. Early ultrasound contrast enhancement of one side of the prostate is interpreted as decreased blood¯ow resistance and identi®ed as the tumour side. The possibi- lities of imaging prostatic blood supply with TRUS have increased with the introduction of ultrasound contrast. First reports on prostate tumour detection and treatment follow up using ultrasound contrasts are encouraging, and further research will reveal the exact clinical value of the evolving technology.
Harmonic imaging
Conventional ultrasound imaging displays structures with different acoustic properties based on amplitudes of re¯ected signals at the fundamental frequency. Development of contrast agents and increasing computer power have provided new imaging techniques that use information of amplitudes at certain frequencies. Conventional microbubble ultrasound contrast acts as an ultrasound blood pool enhancer by basically the same mechanism used with conventional ultrasonography, namely the difference in echo intensity of different tissues. With ultrasound contrast the difference in acoustic impedance between blood, surrounding tissue and the microbubble is increased.
The acoustic wave re¯ection, however, is contaminated with backscatter from surrounding tissue. In particular, the echoes of small vessels, with relatively low¯ow, exist in the midst of echoes of the surrounding solid structures, which are almost always stronger than the contrast enhanced blood¯ow echoes. These signals drown in the clutter of Doppler signals. Burns et al 62 described harmonic imaging as a technique, which could provide a solution for this problem. The technique uses the non-linear vibration of bubbles, which result in a backscatter signal at higher harmonic frequencies. Images are created by transmitting ultrasound at the fundamental transducer frequency but receiving backscatter signals at the second harmonic (which is twice the fundamental frequency). Backscatter signals from the surrounding tissue are mainly of the fundamental frequency, whereas the microbubbles also create backscatter at harmonic frequencies at a stronger level than scattering from areas without contrast agents because of non-linear oscillation. The contaminating backscatter signal of the surrounding tissue is ®ltered in the frequency domain before creating the image.
Second harmonic imaging permits the showing of extremely small vessels (down to 40 mm) with very slow ow, which would be missed with a conventional method. 63 Harmonic imaging to visualise blood vessels has been tested in animal studies 64 as well as in humans. 65, 66 Conventional Doppler transmits sequential pulses along the line of interest and detects differences between the received signals. These signals are then related to¯ow. In harmonic Power Doppler imaging, the changes between re¯ected signals in Doppler imaging are extended by the strong signal occurring during the rupture of microbubbles. As the signals associated with the rupture of the bubbles appear in a range of frequencies, signals that initially drowned in the clutter become visible. These speci®c signatures can be used to distinguish microbubbles from tissue. Harmonic Power Doppler imaging was developed to provide real-time background subtraction. It uses not only the harmonic response from the microbubbles, but their motion, instability, and destruction as well. Multiple pulses arc transmitted down each ray line and the returned signals are subtracted from each other, highlighting change from one pulse to the next, in effect real-time background subtraction. Harmonic Power Doppler imaging combined with controlled existence of contrast agents offer an exciting new ®eld of interest.
The advantage of harmonic imaging, as stated before, is the signature of the microbubbles in the re¯ected signal. The drawback is the limited resolution because the separation of fundamental frequency and second harmonic frequency requires a number of pulses in the transmitting wave. The solution to this problem could be wideband harmonic imaging. Wideband imaging is an extension of the harmonic imaging used so far, designed for use with non-linear ultrasound contrast media. Depending on the non-linear response from microbubbles, this technique uses the full bandwidth of the ultrasound scanner on the receiving side. Early results indicate an improvement over conventional second harmonic imaging. 67 Pulse inversion Doppler imaging, as presented by Hope Simpson et al 68 provides a novel method for improved harmonic imaging. In-vitro measurements suggest that broad band pulse inversion Doppler can provide 3 to 10 dB more agent to tissue contrast than harmonic imaging. The authors conclude that in-vivo experiments are needed to con®rm the predictions and assess the clinical potential of this technique.
Recently, another property of microbubble ultrasound contrast has been observed, a technique known as transient imaging. When a powerful ultrasound beam hits contrast agent microbubbles, they can be ruptured, producing a strong and very short random backscatter echo. This signal is read as a Doppler signal and results in a random Doppler display where the individual microbubbles intentionally dissolve. 69 This stimulated acoustic emission can be used for in¯ow-measurements: after rupture of all microbubbles, the ultrasound transmitter of the scanner is turned off and after a certain time, for example four seconds, turned on again. The number of microbubbles now visible in the image as a random Doppler signal is a measure for tissue perfusion.
Additionally, this technique of destroying microbubbles can have therapeutic application in localised drug delivery when drugs are incorporated inside the microbubbles and destroyed by stimulated acoustic emission at the desired location. 70 
Future prospectives of transrectal ultrasonography
Ultrasonography has become the fastest growing diagnostic imaging modality. Its versatility, portability, low costs and ef®cacy has made ultrasonography an indispensable diagnostic tool in modern patient care. 71 Various new applications and technical improvements are discussed in this section.
One of the options for future application of TRUS might be the follow up of minimally invasive localised therapy for various prostate abnormalities. In this respect, we are investigating the use of contrast enhanced 3D Power Doppler for follow up of ablative treatment with Trans Urethral Microwave Thermotherapy (TUMT) for BPH 72 and High Intensity Focused Ultrasound (HIFU) for prostate carcinoma. 73 With regard to TUMT, we have extensive experience in using the technique and we have treated up to 1200 BPH patients with TUMT from 1990 to 1998. The results of the TUMT show impressive results, but are less pronounced than surgical resection of the prostate. 74 ± 76 The 3D contrast enhanced Power Doppler studies are performed before and after the ablative therapy. The objective is to determine the size of the defect in vascularity created by the ablative therapy by comparing the vascularity images before and after treatment. For TUMT, the relative perfused area of the prostate before treatment could be a predictive value for the outcome of the treatment. If the prostate is hyper-vascular the effect of the heat delivered to the prostate during TUMT might be reduced because of cooling of the prostate by the blood¯o w in the vessels (prostatic radiator effect). Also the size of the defect in vascularity created by the treatment might predict the effect of treatment in the long run. Figure 6 shows the vascularity effect as mentioned. The ®rst image is a 3D contrast enhanced PDU investigation prior to TUMT. A fairly symmetrical vessel distribution is seen, with large periurethral and capsular blood vessels. The second image is the same patient two weeks after TUMT. The periurethral and capsular blood vessels are still clear, but almost no blood vessels are seen in the transitional zone.
Beerlage et al evaluated the ef®cacy of HIFU as a therapy for localised prostate carcinoma by verifying the extension and precise location of the lesions created by HIFU and to assess its side effects. 77 The results showed that extensive coagulative necrosis can be obtained in the treated area. However exact targeting, so that all malignant tissue is treated, is crucial and needs to be guaranteed. We performed a contrast enhanced 3D Power Doppler study as part of a protocol to determine the feasibility of HIFU as a localised ablative therapy for prostate cancer and to determine if we could locate the lesions created by HIFU. Patients scheduled to undergo radical retropubic prostatectomy (RRP) were included in the protocol and one week before RRP an HIFU-treatment was performed. Contrast enhanced 3D Power Doppler imaging was performed before HIFU treatment and before RRP. We compared the size of the defect in vascularity with the histological ®ndings of the RRP specimen. The size of the defect can be used to monitor the desired treatment area, especially if HIFU is used as an ablative mono-therapy for localised prostate cancer. Figure 7 shows the effect of HIFU on the vascularity of the prostate. The ®rst image is a 3D contrast enhanced PDU investigation of a patient with localised prostate cancer, and scheduled to undergo a radical prostatectomy. One week prior to surgery a HIFU treatment was performed. The second image is a 3D contrast enhanced PDU investigation of the same prostate, one week after HIFU and one day prior to surgery. An effect is seen on the vascularity of the prostate. The third image is the radical prostatectomy histology specimen of the prostate. The HIFU effect is outlined as well as the remaining tumour on the left side of the image.
Our ®rst results indicate good correlation between the relative size of the HIFU defect measured with contrast enhanced 3D Doppler ultrasonography and the relative size of the HIFU defect measured in the pathology specimen. 78 Notwithstanding the fact that it is necessary to have a precise location of the tumour within the prostate before a local monotherapy can be successful, this technique for follow up of local treatment can be very useful should such a re-treatment be considered. Technical improvements in ultrasound are currently under development. Some of these improvements will be discussed because of the possible future application of these new modalities in transrectal ultrasound to evaluate prostate diseases.
The ®rst to be mentioned is vibration sonoelastography or elastography. Elastography takes advantage of the fact that different types of tissues respond differently to compression. The basic concept is to propagate lowamplitude and low-frequency shear waves through deep organs and displaying the vibration response in real time using Doppler techniques. A hard inhomogene- ity will produce a disturbance in the vibration response, forming the basis of detection of a tumour, even if it is isoechoic on grey scale ultrasound. 79 Sarvazyan et al 80 described the theoretical and technical aspects of shear wave elasticity imaging. They conclude that many issues including safety must be considered before the method can be used in clinical studies, but it has the potential of a valuable diagnostic tool. It could be an important addition to DRE and TRUS of the prostate.
Two more improvements are speckle reduction and edge enhancement. Both modalities are meant to improve the image quality, by reduction of noise and presenting clearer edges of the object. Zong et al 81 discussed an algorithm for speckle reduction and contrast enhancement. They showed experimentally that the technique for speckle reduction and contrast enhancement produced superior results both qualitatively and quantitatively when compared to existing denoising methods. Further research is needed to indicate the clinical usefulness. Edge detection will be extremely useful in TRUS of the prostate. Many studies have been performed but it has not yet come to clinical application. 82, 83 These examples are just a few improvements in the ®eld of ultrasound. Other research and new technologies will help the physician in interpreting the information of the ultrasound images. It is however the skill and experience of the physician which will ultimately determine the bene®t of ultrasonography in patient care.
Discussion
In the future the number of patients visiting the urologist for prostate diseases will probably increase. The incidence and prevalence of Benign Prostate Hyperplasia (BPH) is also predicted to increase, leading to an increasing number of patients suffering from Lower Urinary Tract Symptoms (LUTS) 84, 85 and increased prostate awareness. The incidence of prostate carcinoma is also expected to increase with ageing of the population although in the US the number of newly detected prostate cancers has declined recent years. Prostate carcinoma may be detected at an early stage because of developments in detection and screening methods. 86, 87 All these prostate conditions will have great effect on health care and have substantial economic implications in the following years.
Several diagnostic tools for prostate carcinoma detection have been developed over the years. Transrectal ultrasonography has a place as an important and easy to use real time imaging modality for the urologist. Volume measurement and ultrasound guidance for prostate biopsies are key applications of TRUS. However, the usefulness of conventional grey scale TRUS for prostate carcinoma detection is limited.
Recent studies have focussed on improving TRUS as a diagnostic tool for detection of prostate carcinoma. Technological innovations and the increase of computer power have resulted in the development of powerful ultrasound scanners. Frequency Doppler ultrasonography and Power Doppler ultrasonography are standard modalities on most new ultrasound scanners. With the addition of 
Figure 7c
The corresponding histology whole mount section of the RRPspecimen. The HIFU (coagulative haemorragic necrosis) effect is encircled. The remaining tumour is also encircled on the right side of the prostate.
contrast agents these modalities may have signi®cant impact on early prostate carcinoma detection and may also provide new insight in tumour vascularity.
The future ultrasound scanners will bene®t from the revolutionary developments in computer technology and digital signal processing. Most of the recent improvements are not based on new physical principles, but rather on innovations in electronics. In particular, high speed digital data processing has revolutionised modern scanners, allowing beams to be formed, and signals to be processed, with unprecedented precision and¯exibility. 88 Promising developments in the near future are believed to be in transducer material and technology and digital signal processing as described by Rizzato. 89 Other promising results are expected from new techniques using contrast enhancement of Doppler and grey scale ultrasonography. The development of new contrast agents with better imaging qualities, combined with prolonged imaging time, are on the horizon. Making use of speci®c acoustic properties of these agents may improve the detection possibilities of the microbubbles with ultrasound. The expected developments in transducer technology combined with contrast enhancement will result in routine use of modalities such as harmonic imaging, triggered transient imaging, harmonic Power Doppler imaging and pulse inversion Doppler imaging, which have already been incorporated in dedicated scanners.
With the prospect of an ageing population of men, with a higher incidence of prostate cancer, often diagnosed at an earlier stage and at a younger age, the need for accurate prostate cancer diagnostics and new treatments is obvious. The conventional curative treatments, radical surgery or external beam radiotherapy, could be considered too aggressive for a subgroup of patients with prostate carcinomas. Localised prostate cancer treatments are under development as an alternative treatment preserving prostate function as well as controlling the cancer. These treatments, by showing a minimum of morbidity and a maximum ef®cacy, might overcome possible treatment`overkill'. In order to allow local treatment to be successful, the clinician must be certain about the exact location of the tumour. Therefore, detection of prostate cancer is of the utmost importance. With the prospect of developing computer and transducer technology, combined with new contrast agents and contrast applications, new possibilities for early detection of prostate cancer are coming into view. Furthermore, monitoring an individual-treatment approach and follow up of treatment ef®cacy are important in order to guarantee adequate treatment. The advantage of TRUS, compared to other imaging diagnostics is its versatility in learning and use, and relative inexpense. The use of contrast agents would increase ultrasound costs, but when contrast agents become available for clinical use, prices of contrast agents might drop. Great efforts are made by engineers and clinicians to develop the ultrasound scanner for the future, with dedicated features for diagnosis, treatment monitoring and evaluation of treatment. The future of ultrasound is very promising and further applications for ultrasound will be more versatile and can revolutionise clinical ultrasound once their use has been proven. However, investigations and investments are needed to ful®l all the predictions concerning the future of ultrasound.
